SYNAPTOGENIX
Synaptogenix is a clinical-stage biotech company leveraging Bryostatin-1 and its analogs to discover and develop targeted therapeutics for neurodegenerative diseases and developmental disorders. The company has targeted Bryostatin-1 due to its high potential and multi-modal efficacy: through protein kinase C (PKCฯต) activation, Bryostatin-1 stimulates synaptic growth factors, amyloid-ฮฒ degrading enzymes, as well as prevents Tau transformation into neurofibrillary tangles.
SYNAPTOGENIX
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
2012-01-01
Status:
Active
Contact:
973-242-0005
Total Funding:
41.5 M USD
Technology used in webpage:
Content Delivery Network Global Site Tag Sitelinks Search Box Yoast WordPress SEO Plugin Yoast Plugins Yoast SEO Premium Pound Sterling Japanese Yen Digital Ocean Global Privacy Control
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Arcellx
Arcellx is a clinical-stage biotechnology company that provides patients with immune cell therapies.
AZTherapies
AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.
Cytokinetics
Cytokinetics is a biopharmaceutical company developing therapies for debilitating diseases.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Eidos Therapeutics
Eidos Therapeutics is a clinical-stage biotech company developing novel, genetically targeted therapies to improve the lives of patients.
PhaseBio Pharmaceuticals
PhaseBio is a clinical-stage biopharmaceutical company that develops drugs for cardiovascular diseases, endocrine, and metabolic disorders.
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Sirnaomics
Sirnaomics is a biopharmaceutical company developing therapeutics for critical human diseases by using RNA interference technology.
Current Employees Featured
Founder
Stock Details
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2023-11-02 | CannaSoul Analytics | Synaptogenix investment in Venture Round - CannaSoul Analytics | 4 M USD |
More informations about "Synaptogenix"
Synaptogenix - Crunchbase Investor Profile & Investments
Synaptogenix is a clinical-stage biotech company leveraging Bryostatin-1 and its analogs to discover and develop targeted therapeutics for neurodegenerative diseases and โฆSee details»
Investor Relations - Synaptogenix
Synaptogenix, Inc. seeks to enhance shareholder value not only through exceptional business performance and practices, but also through responsible and effective communication with its shareholders. The latest company โฆSee details»
Synaptogenix, Inc. (SNPX) Company Profile & Facts - Yahoo Finance
See the company profile for Synaptogenix, Inc. (SNPX) including business summary, industry/sector information, number of employees, business summary, corporate governance, โฆSee details»
Pioneers of Restorative Therapeutics - Synaptogenix
Synaptogenix is a clinical-stage biopharmaceutical company discovering restorative, novel therapeutics for patients with life-altering neurodegenerative diseases and developmental โฆSee details»
Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe ...
Jul 13, 2023 Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World โฆSee details»
Synaptogenix, Inc. (SNPX) Company Profile & Overview - Stock โฆ
Nov 19, 2024 The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome. The company was โฆSee details»
Synaptogenix, Inc. (SNPX) Company Profile & Facts - Yahoo Finance
Synaptogenix, Inc. operates as a clinical-stage biopharmaceutical company. It is conducting clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's โฆSee details»
Synaptogenix - Funding, Financials, Valuation & Investors
Synaptogenix is a clinical-stage biopharmaceutical company that develops novel therapies for neurodegenerative diseases. Search Crunchbase. Start Free Trial . ... How much funding has โฆSee details»
Neurotrope completes formation of new company Synaptogenix
Dec 14, 2020 Neurotrope announced the completion of an independent spin-off of neurotrope bioscience, which has now been renamed as Synaptogenix, trading under the symbol SNPX. โฆSee details»
Synaptogenix Company Profile - Office Locations, Competitors
Oct 22, 2024 Synaptogenix (formerly known as Neurotrope Bioscience) is a biopharmaceutical company that specializes in therapies for neurodegenerative diseases. It develops a product โฆSee details»
Neurotrope, Inc. Completes Independent Spin-off of Neurotrope ...
NEW YORK, Dec. 8, 2020 /PRNewswire/ -- Synaptogenix, Inc. (OTC: SNPX), formerly Neurotrope Bioscience, Inc., today announced the successful spin-off of substantially all of the โฆSee details»
1st Alzheimer's Patient Given Bryostatin in Dose-finding Trial
Jul 25, 2022 โWhile the current dosing has been found to produce clear cognitive improvement over baseline, the company has planned a dose-ranging study to optimize the extent and โฆSee details»
Synaptogenix Announces Peer-Reviewed Publication of NIH โฆ
Sep 26, 2023 Synaptogenix, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for neurodegenerative disorders. The Company is principally focused on โฆSee details»
Synaptogenix Increases Stake in Innovative Psilocybin Drug โฆ
Apr 9, 2024 Synaptogenix, through its partnership with Cannasoul, expanded its stake in PsygaBio, enabling Synaptogenix Chairman Josh Silverman and Director Bruce Bernstein to โฆSee details»
Home v1 - Synaptogenix
Synaptogenix is a clinical-stage biotech company leveraging Bryostatin-1 and its analogues to discover and develop targeted therapeutics for neurodegenerative diseases and โฆSee details»
Synaptogenix, Inc. (SNPX) Stock Price, News, Quote & History
Synaptogenix, Inc. operates as a clinical-stage biopharmaceutical company. It is conducting clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's โฆSee details»
Synaptogenix Moves Forward with Clinical Development Plans for ...
Feb 23, 2022 Synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases. Synaptogenix has โฆSee details»
Synaptogenix, Inc. (SNPX) Stock Price, Quote & News - Stock โฆ
Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of โฆSee details»
SNPX - Synaptogenix Inc Stock Price and Quote - FINVIZ.com
Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced โฆSee details»